Cargando…
Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
Autores principales: | Okoye, Christian C., Cho, C. Jane, Liu, Mitchell, Louie, Alexander V., Obayomi-Davies, Olusola, Siva, Shankar, Lo, Simon S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576082/ https://www.ncbi.nlm.nih.gov/pubmed/33241046 http://dx.doi.org/10.21037/atm-20-3149 |
Ejemplares similares
-
Complications from Stereotactic Body Radiotherapy for Lung Cancer
por: Kang, Kylie H., et al.
Publicado: (2015) -
Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019) -
Stereotactic Body Radiotherapy for Primary Prostate Cancer
por: Kothari, Gargi, et al.
Publicado: (2018) -
Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
por: Tran, Kevin T., et al.
Publicado: (2023) -
Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors
por: Lischalk, Jonathan W., et al.
Publicado: (2018)